CTOs on the Move


 
Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of CNS disorders. Axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. The company is based in New York City.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.axsome.com
  • 200 Broadway 3rd Floor
    New York, NY USA 10004
  • Phone: 212.332.3241

Executives

Name Title Contact Details
Mark Jacobson
Chief Operating Officer Profile

Funding

Axsome raised $200M on 12/23/2019

Similar Companies

Tri State Surgical Supply

Tri State Surgical Supply is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Autolus

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Octapharma USA

Octapharma is committed to promoting excellence in patient care and providing valuable information to the medical and patient community. This will help to better manage the treatment of disease and to improve patient safety and population health

Onconova

Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. Onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.

BioMotiv

BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.